Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 10/20 | 0.64 |
| ▸ | SPHK2 | Q9NRA0 | 9/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342866 | 1.00 | SPHK1 (0.64) | SPHK1SPHK2OPRD1GBA1 | |
| SCHEMBL1051602 | 1.00 | SPHK1 (0.64) | SPHK1SPHK2OPRD1GBA1 | |
| SCHEMBL2169692 | 0.95 | SPHK1 (0.69) | SPHK1SPHK2 | |
| SCHEMBL4926619 | 0.95 | SPHK1 (0.69) | SPHK1SPHK2 | |
| SCHEMBL312540 | 0.95 | SPHK1 (0.69) | SPHK1SPHK2 | |
| Acetic Acid SCHEMBL7448428 | 0.93 | OPRD1 (0.59) | SPHK1SPHK2OPRD1 | |
| SCHEMBL19823120 | 0.91 | SPHK1 (0.58) | SPHK1SPHK2 | |
| Biphenyl SCHEMBL27478734 | 0.90 | SPHK1 (0.64) | SPHK1SPHK2 | |
| SCHEMBL7576557 | 0.88 | GBA1 (0.59) | SPHK1SPHK2GBA1 | |
| SCHEMBL17141385 | 0.88 | GBA1 (0.59) | SPHK1SPHK2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358710-B1 | AKT AND P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8148387-B2 | AKT and P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-7928125-B2 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-19 | — | — | US | disclosed |
| US-7928124-B2 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-19 | — | — | US | disclosed |
| US-7897618-B2 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-7893090-B2 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2011-02-22 | — | — | US | disclosed |
| US-20100168143-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB | 2010-07-01 | — | — | US | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
| US-20090036442-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. | 2009-02-05 | — | — | US | disclosed |
| US-20090012083-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-20090012122-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-20080318944-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. | 2008-12-25 | — | — | US | disclosed |
| EP-1705179-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2006-09-27 | — | — | EP | disclosed |
| EP-1399441-B1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2006-07-05 | — | — | EP | disclosed |
| EP-1399441-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002561-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, MTOR | SPHK1 725/4885SPHK2 621/4885OPRD1 2967/4885 |
| US-20090012122-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | SPHK1 882/4885SPHK2 780/4885OPRD1 35/4885 |
| US-20080318944-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | SPHK1 882/4885SPHK2 780/4885OPRD1 35/4885 |
| US-20090012083-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | SPHK1 882/4885SPHK2 780/4885OPRD1 35/4885 |
| US-20090036442-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | SPHK1 882/4885SPHK2 780/4885OPRD1 35/4885 |
| US-20100168143-A1 | QUINAZOLINE DERIVATIVES | CCNI, NQO2, MKI67 | SPHK1 2229/4885SPHK2 2310/4885OPRD1 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.